Mirabegron: first β3 agonist in treatment of overactive bladder

Paramdeep Singh Gill, Nipunjot Grewal

Abstract


Mirabegron is the first and only β3 agonist approved by US FDA in June 2012 for treatment of Overactive bladder with symptoms of urge incontinence, urgency and urinary frequency. It is the first oral OAB treatment with a distinct mechanism of action since the launch of anticholinergic agents 30 years ago. It causes relaxation of detrusor smooth muscle by its agonist action at β3 receptors leading to increased storage capacity of bladder. It has been studied extensively in more than 10,000 individuals over 10 years.


Keywords


Overactive bladder, Anticholinergics, β3 agonist

Full Text:

PDF

References


Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.

Lapitan MC, Chye PL. The epidemiology of overactive bladder among females in Asia: a questionnaire survey. Int Urogynecol J Pelvic Floor Dysfunct 2001;12:226-31.

Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991;265:609-13.

Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841-4.

Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000;85 Suppl 3:57-68.

Myrbetriq (Mirabegron) prescribing information. Available at http://www.us.astellas.com/docs/myrbetriq-full-pi.pdf. Accessed 19 September 2012.